[{"id":100409,"version":67,"name":"CFTR and Ivacaftor","url":"https://www.clinpgx.org/guideline/PA166251449","genes":["CFTR"],"notesonusage":null,"clinpgxid":"PA166251449","publication":[{"pmid": "24598717", "year": 2014, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Ivacaftor Therapy in the Context of CFTR Genotype"}]}, 
 {"id":104245,"version":65,"name":"CYP2B6 and efavirenz","url":"https://www.clinpgx.org/guideline/PA166251463","genes":["CYP2B6"],"notesonusage":null,"clinpgxid":"PA166251463","publication":[{"pmid": "31006110", "year": 2019, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-containing Antiretroviral Therapy."}]}, 
 {"id":5290481,"version":23,"name":"CYP2B6 and methadone","url":"https://www.clinpgx.org/guideline/PA166411641","genes":["CYP2B6"],"notesonusage":null,"clinpgxid":"PA166411641","publication":[{"pmid": "38863207", "year": 2024, "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2B6 Genotype and Methadone Therapy."}]}, 
 {"id":100411,"version":67,"name":"CYP2C19 and Clopidogrel","url":"https://www.clinpgx.org/guideline/PA166251443","genes":["CYP2C19"],"notesonusage":null,"clinpgxid":"PA166251443","publication":[{"pmid": "21716271", "year": 2011, "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450-2C19 (CYP2C19) Genotype and Clopidogrel Therapy"}, {"pmid": "35034351", "year": 2022, "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update."}, {"pmid": "23698643", "year": 2013, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy: 2013 Update"}]}, 
 {"id":110076,"version":64,"name":"CYP2C19 and Proton Pump Inhibitors","url":"https://www.clinpgx.org/guideline/PA166251441","genes":["CYP2C19"],"notesonusage":null,"clinpgxid":"PA166251441","publication":[{"pmid": "32770672", "year": 2020, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing."}]}, 
 {"id":100410,"version":67,"name":"CYP2C19 and Voriconazole","url":"https://www.clinpgx.org/guideline/PA166251456","genes":["CYP2C19"],"notesonusage":null,"clinpgxid":"PA166251456","publication":[{"pmid": "27981572", "year": 2016, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guideline for CYP2C19 and Voriconazole Therapy"}]}, 
 {"id":100414,"version":67,"name":"CYP2D6, CYP2C19 and Tricyclic Antidepressants","url":"https://www.clinpgx.org/guideline/PA166251445","genes":["CYP2C19","CYP2D6"],"notesonusage":null,"clinpgxid":"PA166251445","publication":[{"pmid": "23486447", "year": 2013, "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants"}, {"pmid": "27997040", "year": 2016, "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC®) for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants: 2016 Update"}]}, 
 {"id":100413,"version":21,"name":"CYP2D6, CYP2C19, CYP2B6, SLC6A4, HTR2A and Serotonin Reuptake Inhibitor Antidepressants","url":"https://www.clinpgx.org/guideline/PA166251452","genes":["CYP2D6","CYP2C19","CYP2B6","SLC6A4","HTR2A"],"notesonusage":null,"clinpgxid":"PA166251452","publication":[{"pmid": "37032427", "year": 2023, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants."}, {"pmid": "25974703", "year": 2015, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors"}]}, 
 {"id":100418,"version":67,"name":"CYP3A5 and Tacrolimus","url":"https://www.clinpgx.org/guideline/PA166251451","genes":["CYP3A5"],"notesonusage":null,"clinpgxid":"PA166251451","publication":[{"pmid": "25801146", "year": 2015, "title": "Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing"}]}, 
 {"id":100419,"version":68,"name":"DPYD and Fluoropyrimidines","url":"https://www.clinpgx.org/guideline/PA166251462","genes":["DPYD"],"notesonusage":null,"clinpgxid":"PA166251462","publication":[{"pmid": "23988873", "year": 2013, "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing"}, {"pmid": "29152729", "year": 2017, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update"}]}, 
 {"id":2405438,"version":63,"name":"G6PD","url":"https://www.clinpgx.org/guideline/PA166251450","genes":["G6PD"],"notesonusage":null,"clinpgxid":"PA166251450","publication":[{"pmid": "24787449", "year": 2014, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the context of G6PD Deficiency Genotype"}, {"pmid": "36049896", "year": 2022, "title": "Expanded Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Medication Use in the Context of G6PD Genotype."}]}, 
 {"id":100423,"version":67,"name":"HLA-A, HLA-B and Carbamazepine and Oxcarbazepine","url":"https://www.clinpgx.org/guideline/PA166251448","genes":["HLA-A","HLA-B"],"notesonusage":null,"clinpgxid":"PA166251448","publication":[{"pmid": "29392710", "year": 2018, "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update."}, {"pmid": "23695185", "year": 2013, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Carbamazepine Dosing"}]}, 
 {"id":6478852,"version":14,"name":"NAT2 and Hydralazine","url":"https://www.clinpgx.org/guideline/PA166416361","genes":["NAT2"],"notesonusage":null,"clinpgxid":"PA166416361","publication":[{"pmid": "40974042", "year": 2025, "title": "Clinical Pharmacogenetics Implementation Consortium Guideline for NAT2 Genotype and Hydralazine Therapy."}]}, 
 {"id":110058,"version":65,"name":"CYP2C9 and NSAIDs","url":"https://www.clinpgx.org/guideline/PA166251464","genes":["CYP2C9"],"notesonusage":null,"clinpgxid":"PA166251464","publication":[{"pmid": "32189324", "year": 2020, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and Nonsteroidal Anti-inflammatory Drugs."}]}, 
 {"id":100412,"version":67,"name":"CYP2C9, HLA-B and Phenytoin","url":"https://www.clinpgx.org/guideline/PA166251461","genes":["CYP2C9","HLA-B"],"notesonusage":null,"clinpgxid":"PA166251461","publication":[{"pmid": "25099164", "year": 2014, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C9 and HLA-B Genotype and Phenytoin Dosing"}, {"pmid": "32779747", "year": 2020, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update."}]}, 
 {"id":100425,"version":68,"name":"CYP2C9, VKORC1, CYP4F2 and Warfarin","url":"https://www.clinpgx.org/guideline/PA166251465","genes":["CYP2C9","CYP4F2","VKORC1"],"notesonusage":"Warfarin recommendation does not follow simple diplotype to phenotype translation. Read the guideline text and follow the recommendation diagram found at http://files.cpicpgx.org/images/warfarin/warfarin_recommendation_diagram.png","clinpgxid":"PA166251465","publication":[{"pmid": "28198005", "year": 2017, "title": "Clinical pharmacogenetics implementation consortium (cpic) guideline for pharmacogenetics-guided warfarin dosing: 2017 update"}, {"pmid": "21900891", "year": 2011, "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 Genotypes and Warfarin Dosing"}]}, 
 {"id":104243,"version":67,"name":"CYP2D6 and Atomoxetine","url":"https://www.clinpgx.org/guideline/PA166251459","genes":["CYP2D6"],"notesonusage":null,"clinpgxid":"PA166251459","publication":[{"pmid": "30801677", "year": 2019, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Atomoxetine Therapy."}]}, 
 {"id":100417,"version":67,"name":"CYP2D6 and Ondansetron and Tropisetron","url":"https://www.clinpgx.org/guideline/PA166251457","genes":["CYP2D6"],"notesonusage":null,"clinpgxid":"PA166251457","publication":[{"pmid": "28002639", "year": 2016, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of Ondansetron and Tropisetron"}]}, 
 {"id":100415,"version":67,"name":"CYP2D6 and Tamoxifen","url":"https://www.clinpgx.org/guideline/PA166251458","genes":["CYP2D6"],"notesonusage":null,"clinpgxid":"PA166251458","publication":[{"pmid": "29385237", "year": 2018, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy."}]}, 
 {"id":100416,"version":68,"name":"CYP2D6, OPRM1, COMT, and Opioids","url":"https://www.clinpgx.org/guideline/PA166251454","genes":["CYP2D6","COMT","OPRM1"],"notesonusage":null,"clinpgxid":"PA166251454","publication":[{"pmid": "22205192", "year": 2011, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype"}, {"pmid": "24458010", "year": 2014, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for cytochrome P450 2D6 (CYP2D6) genotype and codeine therapy: 2014 Update"}, {"pmid": "33387367", "year": 2021, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, OPRM1, and COMT genotype and select opioid therapy."}]}, 
 {"id":5290480,"version":23,"name":"CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 and Beta-Blockers","url":"https://www.clinpgx.org/guideline/PA166343383","genes":["CYP2D6","ADRB1","ADRB2","ADRA2C","GRK4","GRK5"],"notesonusage":null,"clinpgxid":"PA166343383","publication":[{"pmid": "38951961", "year": 2024, "title": "Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy."}]}, 
 {"id":100421,"version":67,"name":"HLA-B and Abacavir","url":"https://www.clinpgx.org/guideline/PA166251444","genes":["HLA-B"],"notesonusage":null,"clinpgxid":"PA166251444","publication":[{"pmid": "22378157", "year": 2012, "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing"}, {"pmid": "24561393", "year": 2014, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B Genotype and Abacavir Dosing: 2014 update"}]}, 
 {"id":100422,"version":67,"name":"HLA-B and Allopurinol","url":"https://www.clinpgx.org/guideline/PA166251446","genes":["HLA-B"],"notesonusage":null,"clinpgxid":"PA166251446","publication":[{"pmid": "23232549", "year": 2012, "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing"}, {"pmid": "26094938", "year": 2015, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update"}]}, 
 {"id":100424,"version":68,"name":"IFNL3 and Peginterferon-alpha-based Regimens","url":"https://www.clinpgx.org/guideline/PA166251455","genes":["IFNL3"],"notesonusage":null,"clinpgxid":"PA166251455","publication":[{"pmid": "24096968", "year": 2013, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and peginterferon alpha based regimens"}]}, 
 {"id":826283,"version":65,"name":"MT-RNR1 and Aminoglycosides","url":"https://www.clinpgx.org/guideline/PA166251466","genes":["MT-RNR1"],"notesonusage":null,"clinpgxid":"PA166251466","publication":[{"pmid": "34032273", "year": 2021, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for the use of aminoglycosides based on MT-RNR1 genotype."}]}, 
 {"id":100427,"version":67,"name":"RYR1, CACNA1S and Volatile anesthetic agents and Succinylcholine","url":"https://www.clinpgx.org/guideline/PA166251460","genes":["CACNA1S","RYR1"],"notesonusage":null,"clinpgxid":"PA166251460","publication":[{"pmid": "30499100", "year": 2018, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the use of potent volatile anesthetic agents and succinylcholine in the context of RYR1 or CACNA1S genotypes"}]}, 
 {"id":100426,"version":68,"name":"SLCO1B1, ABCG2, CYP2C9, and Statins","url":"https://www.clinpgx.org/guideline/PA166264281","genes":["SLCO1B1","ABCG2","CYP2C9"],"notesonusage":null,"clinpgxid":"PA166264281","publication":[{"pmid": "24918167", "year": 2014, "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update"}, {"pmid": "22617227", "year": 2012, "title": "The Clinical Pharmacogenomics Implementation Consortium: Guideline for SLCO1B1 and Simvastatin-Induced Myopathy"}, {"pmid": "35152405", "year": 2022, "title": "The Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for SLCO1B1, ABCG2, and CYP2C9 and statin-associated musculoskeletal symptoms."}]}, 
 {"id":100428,"version":67,"name":"TPMT, NUDT15 and Thiopurines","url":"https://www.clinpgx.org/guideline/PA166251442","genes":["NUDT15","TPMT"],"notesonusage":null,"clinpgxid":"PA166251442","publication":[{"pmid": "30447069", "year": 2018, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update."}, {"pmid": "21270794", "year": 2011, "title": "Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing"}, {"pmid": "23422873", "year": 2013, "title": "Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update"}, {"pmid": "41618934", "year": 2026, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2025 Update."}]}, 
 {"id":100429,"version":67,"name":"UGT1A1 and Atazanavir","url":"https://www.clinpgx.org/guideline/PA166251453","genes":["UGT1A1"],"notesonusage":null,"clinpgxid":"PA166251453","publication":[{"pmid": "26417955", "year": 2015, "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing"}]}]